{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"Will be defined as the number of patients having either complete response (CR), partial response (PR), or stable disease for at least 6 months after starting treatment. The frequencies and rates of tumor response categories (CR, PR, SD, PD, and too early/not evaluated) will be summarized by dose cohort and treatment arm. Complete Response (CR): All of the following must be true: a. Disappearance of all target lesions. b. Each target lymph node must have reduction in short axis to \\< 1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD taking as reference the BSD. Progression (PD): At least one of the following must be true: a. At least one new malignant lesion,b. At least a 20% increase in PBSD. c. PD via FDG-PET imaging. d. unequivocal progression of existing non-target lesions and non-target lymph nodes. e. symptomatic deterioration. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD taking as reference the MSD.","groups":[{"description":"Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly over a 4-week cycle.","id":"OG000","title":"Phase II - Analysis Group 2 MLN0128"},{"description":"Patients receive 400mg Pazopanib orally once daily over a 4-week cycle and titrated to tolerance (maximum 800mg) by the treating physician in the first intervention period/initial treatment period.","id":"OG001","title":"Phase II - Analysis Group 2 Pazopanib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Phase II Analysis Group 2 - Initial Treatment Period","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Number of Patients Having CR, PR, or SD at 6 Months (Phase II Analysis Group 2 - Initial Treatment Period)","type":"SECONDARY","unitOfMeasure":"Participants"}